TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination is a research paper published in Journal of Clinical Investigation (2020). On theSindex it has a DataRank of 0. It has been cited 85 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Comprehensive Cancer Center, University of Michigan
Grant: UM Cancer Center- Cancer Center Support Grant (P30 CA046592)
Breast Cancer Research Foundation
Grant: AWD007734
National Cancer Institute
Grant: T32 CA140044
NCI NIH HHS
Grant: T32 CA009676
NIGMS NIH HHS
Grant: T32 GM113900
NCI NIH HHS
Grant: P30 CA046592
NIGMS NIH HHS
Grant: T32 GM007315
NIGMS NIH HHS
Grant: T32 GM007767
FWCI
4.32
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
Additional file 1 of TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
Additional file 1 of Therapeutic targeting of the TPX2/TTK network in colorectal cancer
Additional file 1 of Therapeutic targeting of the TPX2/TTK network in colorectal cancer
Additional file 2 of Therapeutic targeting of the TPX2/TTK network in colorectal cancer
Additional file 2 of Therapeutic targeting of the TPX2/TTK network in colorectal cancer
Additional file 1 of Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer
Additional file 1 of Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer